RECOVERY trial
Research type
Research Study
Full title
Randomised Evaluation of COVID-19 Therapy (RECOVERY)
IRAS ID
281712
Contact name
Peter Horby
Contact email
Sponsor organisation
University of Oxford
Eudract number
2020-001113-21
ISRCTN Number
ISRCTN50189673
Duration of Study in the UK
10 years, 6 months, 11 days
Research summary
Background: In early 2020, as this protocol was being developed, there were no approved treatments for COVID-19, a disease induced by the novel coronavirus SARS-CoV-2 that emerged in China in late 2019. The UK New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) advised that several possible treatments should be evaluated, including Lopinavir-Ritonavir, Interferon β, corticosteroids, and Remdesivir. These groups also advised that other treatments will soon emerge that require evaluation. A World Health Organization (WHO) expert group issued broadly similar advice.
Eligibility and randomisation: This protocol describes a randomised trial among adults hospitalised for confirmed COVID-19. Eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital: No additional treatment vs Lopinavir-Ritonavir vs low-dose corticosteroids vs hydroxychloroquine vs azithromycin. For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms.
Outcomes: The main outcomes will be death within 28 days of randomisation, discharge, and need for ventilation. For the main analyses, follow-up will be censored at 28 days after admission. Additional information on longer term outcomes may be collected through review of medical records or linkage to medical databases such as those managed by NHS Digital and equivalent organisations in the devolved nations.
Outcomes: The main outcomes will be in-hospital death, discharge, and need for ventilation. For the main analyses, follow-up will be censored at 28 days after admission. Additional information on longer term outcomes may be collected through review of medical records or linkage to medical databases such as those managed by NHS Digital and equivalent organisations in the devolved nations.
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
20/EE/0101
Date of REC Opinion
17 Mar 2020
REC opinion
Favourable Opinion